RE:RE:RE:RE:RE:RE:Trodelvy's most direct competitor in TNBC Ph 1 data releasedInteresting stains. I toyed around with this too, getting nowhere. But one thing that seemed to be true as I compared other targets is that it appears sortilin is in fairly low levels normally and has some concentration in the brain and a few other organs. It doesn't appear to be in concentration in many places in the body.
Secondly, it seems the differential becomes extremely large around the tumor environment, especially in those advanced cases they are targeting. This may help it stay fairly "on target" and have fewer side effects. But I can't say I know how either of those compares to other targets used. It may be similar, it may be uniquely good for the purpose. My guess is those traits are no worse than any others being used for solid tumors, and for the advanced cases where the unmet need is, it may be better given the large overexpression the tumor environment causes. But I'm ok just thinking it's similar to others at worst, until someone can be more definitive around it.
jfm1330 wrote: One thing Thera did not explain, and I made some research about that on the net to find some answers, is how sortilin expression compare to other receptors expression that are targets for other PDCs and ADCs. I did not find any data where you would be able to compare the levels of receptors expression.The only thing I found is a visual comparison from histological staining of sortilin expression in breast cancers from two levels of low expression (1 and 2) and two levels of high expression (3 and 4). One thing is sure, just within the possible sortilin expression levels, the differences of expression are huge. If you have level 4 of sortilin expression, it is hard to imagine how TH1902 would not be much more efficacious, if you put aside other possible factors like docetaxel resistance.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-07854-0/figures/1